Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
100 hedge funds and large institutions have $303M invested in Y-mAbs Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
10% more funds holding
Funds holding: 91 → 100 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
2.75% less ownership
Funds ownership: 56.64% → 53.89% (-2.8%)
8% less capital invested
Capital invested by funds: $330M → $303M (-$26.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.92M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.91M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.29M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.81M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$6.97M |
| 4 |
Morgan Stanley
New York
|
-$1.97M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.63M |
YMAB Hedge Fund Activity: Q3 2022 in Review
100 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2022, worth a combined $303M — down 8.1% from $330M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new YMAB positions and 7 closed out — a net gain of 9 holders — while 29 added to existing stakes and 32 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.92M. The largest seller was AllianceBernstein, cutting an estimated $11M.
- 100 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2022, up from 91 in Q2 2022.
- Funds reported $303M of Y-mAbs Therapeutics stock for Q3 2022, down 8.1% quarter-over-quarter.
- 16 funds opened new Y-mAbs Therapeutics positions in Q3 2022 and 7 closed out, a net change of +9 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2022 was Driehaus Capital Management, an estimated $4.92M added.
- The largest Y-mAbs Therapeutics seller in Q3 2022 was AllianceBernstein, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2022.